AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC-inhibitors
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR-alpha and -gamma agonists
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase (PDE-5) inhibitors
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins plus ACE inhibitors
Number of subjects: 0
Study 17654442 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins plus fibrates
Number of subjects: 0
Study 15206277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autoblood reservation (7-8 ml/kg)
Number of subjects: 109
Study 15206277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative autoblood reservation)
Number of subjects: 109
Study 11529211 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated jugular venous pressure
Number of subjects: 2479
Study 11529211 — intervention group
Group type: EXPERIMENTAL
Intervention: Third heart sound
Number of subjects: 2479
Study 11529211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2479
Study 11529211 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2479
Study 9672338 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Number of subjects: 168
Study 9672338 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.i.d. plus tetracycline 500 mg q.i.d. plus metronidazole 500 mg t.i.d. (RBC-TET-MET)
Number of subjects: 168
Study 9672338 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.i.d. plus amoxycillin 1000 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-AMO-CLA)
Number of subjects: 168
Study 9672338 — intervention group
Group type: COMPARATOR
Intervention: 14-day RBC 400 mg b.i.d. plus clarithromycin 500 mg b.i.d. (RBC-CLA)
Number of subjects: 168
Study 7943693 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of mivacurium after complete recovery from > 95% neuromuscular block
Number of subjects: 0
Study 7943693 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of mivacurium after 100 s exclusion from peak effect
Number of subjects: 0
Study 2638184 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 91
Study 2638184 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 91
Study 4265057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 933
Study 31206749 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal implant placement (Group-A)
Number of subjects: 46
Study 31206749 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft (CTG) over the implant neck (Group-B)
Number of subjects: 46
Study 31206749 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin mucosa grafted Subgroups (Group-AI/Group-BI)
Number of subjects: 46
Study 29507283 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 27
Study 27263418 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystal music intervention
Number of subjects: 70
Study 27263418 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (control)
Number of subjects: 70
Study 24622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Balance Training (FBT)
Number of subjects: 0
Study 24622155 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study 24622155 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 0
Study 22159695 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal biofeedback (AB)
Number of subjects: 21
Study 22159695 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback control (BC)
Number of subjects: 21
Study 20214062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment with alternative use of two groups of acupoints and electroacupuncture in disperse-dense wave for 30 min
Number of subjects: 63
Study 17068074 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention
Number of subjects: 131
Study 17068074 — intervention group
Group type: COMPARATOR
Intervention: Standard services (Control)
Number of subjects: 131
Study 15361516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycogen training protocol
Number of subjects: 7
Study 15361516 — intervention group
Group type: COMPARATOR
Intervention: High glycogen training protocol
Number of subjects: 7
Study 12201386 — intervention group
Group type: EXPERIMENTAL
Intervention: VLT play (90 min)
Number of subjects: 30
Study 12201386 — intervention group
Group type: COMPARATOR
Intervention: Control activity (viewing a movie)
Number of subjects: 30
Study 10774129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality synthesized speech (DECtalk Express)
Number of subjects: 193
Study 10774129 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-quality synthesized speech (Monologue)
Number of subjects: 193
Study 10774129 — intervention group
Group type: COMPARATOR
Intervention: Human voice (control)
Number of subjects: 193
Study 7745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms gonadotrophin‐releasing hormone (GnRH)
Number of subjects: 38
Study 7745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms GnRH agonist (GnRHa)
Number of subjects: 38
Study 7745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU human chorionic gonadotrophin (HCG)
Number of subjects: 38
Study 7745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms GnRH
Number of subjects: 38
Study 2032746 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired filtration dialysis (PFD) 3x3 h/wk with 0.4 m2 polysulphone (PS) and 1.36 m2 cuprophan (CU)
Number of subjects: 0
Study 2032746 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired filtration dialysis (PFD) 3x4 h/wk with 0.4 m2 polysulphone (PS) and 1.06 m2 cuprophan (CU)
Number of subjects: 0
Study 2032746 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD) 3x4 h/wk with 1.36 m2 cuprophan (CU)
Number of subjects: 0
Study 6118058 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE‐2 aerosol in alcohol solution
Number of subjects: 50
Study 6118058 — intervention group
Group type: COMPARATOR
Intervention: Placebo of ethyl alcohol
Number of subjects: 50
Study 6118058 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol and ethyl alcohol aerosol
Number of subjects: 50
Study 31701485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 0
Study 31701485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30838781 — intervention group
Group type: EXPERIMENTAL
Intervention: iPex II
Number of subjects: 60
Study 30838781 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 60
Study 30838781 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex ID
Number of subjects: 60
Study 30838781 — intervention group
Group type: COMPARATOR
Intervention: Control (Intraoral periapical radiograph)
Number of subjects: 60
Study 27889332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (two 30‐min sessions per week for 4 months)
Number of subjects: 116
Study 27889332 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study 25526757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole 750 mg plus miconazole 200 mg
Number of subjects: 234
Study 25526757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 24561148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1299
Study 24561148 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1299
Study 22446438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 25
Study 22446438 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 25
Study 21046988 — intervention group
Group type: EXPERIMENTAL
Intervention: Livina (2 capsules twice daily) with ATT
Number of subjects: 0
Study 21046988 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ATT
Number of subjects: 0
Study 17987463 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted diesel exhaust (DE) inhalation (200 microg/m(3) of fine particulate matter)
Number of subjects: 5
Study 17987463 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 5
Study 15955903 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (269 patients)
Number of subjects: 553
Study 15955903 — intervention group
Group type: COMPARATOR
Intervention: No thalidomide (284 patients)
Number of subjects: 553
Study 15955903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dexamethasone dose
Number of subjects: 553
Study 15955903 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 553
Study 15955903 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 553
Study 12078468 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group listened to a word list and short story selection.
Number of subjects: 0
Study 12078468 — intervention group
Group type: COMPARATOR
Intervention: Control group listened to tapes of white noise.
Number of subjects: 0
Study 9860145 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine infusion
Number of subjects: 16
Study 7719388 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Heart Health Program (MHHP) community intervention activities including risk factor screening, mass media education, adult education classes, worksite interventions, home correspondence programs, school‐based programs, restaurant programs, and point‐of‐purchase education in supermarkets.
Number of subjects: 0
Study 7719388 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched communities without the MHHP intervention)
Number of subjects: 0
Study 2223582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TM), 30 mg per day for 2 years
Number of subjects: 308
Study 2223582 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 308
Study 2223582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TM)
Number of subjects: 308
Study 7368968 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin, 5 000 IU twice daily
Number of subjects: 99
Study 7368968 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 99
Study 30411542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education format (13.5 h over two consecutive days)
Number of subjects: 48
Study 30411542 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive education format (sequential 90-min tutorials delivered 1 week apart)
Number of subjects: 48
Study 28425827 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + glycine powder air-polishing (GPAP)
Number of subjects: 60
Study 28425827 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 60
Study 25874236 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 206
Study 25874236 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 206
Study 23338656 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle crossing training
Number of subjects: 20
Study 23338656 — intervention group
Group type: COMPARATOR
Intervention: Overground walking training
Number of subjects: 20
Study 17326161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (75-100 mg/day)
Number of subjects: 21
Study 17326161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15016017 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day full-mouth scaling and root planing (FM-SRP)
Number of subjects: 40
Study 15016017 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 40
Study 15016017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FM-SRP and Q-SRP
Number of subjects: 40
Study 11035676 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (FM), 12 microg, for 2 weeks and FM, 24 microg, for 2 weeks
Number of subjects: 15
Study 11035676 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 400 microg, for 2 weeks and BUD, 800 microg, for 2 weeks
Number of subjects: 15
Study 11035676 — intervention group
Group type: EXPERIMENTAL
Intervention: FM, 12 microg, plus BUD, 400 microg, for 2 weeks and FM, 24 microg, plus BUD, 800 microg, for 2 weeks
Number of subjects: 15
Study 11035676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11035676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (FM plus BUD)
Number of subjects: 15
Study 11035676 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatments (FM, BUD, FM plus BUD)
Number of subjects: 15
Study 8736460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg, orally)
Number of subjects: 20
Study 8736460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1302543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cang Dou Pill
Number of subjects: 648
Study 1302543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 648
Study 3927691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (average daily dosage 89 mg, range 40 to 160)
Number of subjects: 17
Study 3927691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3927691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 17
Study 31631215 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid substitution treatment (OST)
Number of subjects: 2466
Study 31655598 — intervention group
Group type: EXPERIMENTAL
Intervention: OSCAR intervention (monthly structured interviews by Social Care Nurses)
Number of subjects: 350
Study 31655598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured interviews)
Number of subjects: 350
Study 31655598 — intervention group
Group type: EXPERIMENTAL
Intervention: OSCAR intervention
Number of subjects: 350
Study 31655598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 350
Study 29292259 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask ventilation with 100% oxygen (Group 1, FiO2=1)
Number of subjects: 80
Study 29292259 — intervention group
Group type: COMPARATOR
Intervention: Face mask ventilation with air (Group 2, FiO2=0.21)
Number of subjects: 80
Study 25883112 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 32
Study 25883112 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 32
Study 25883112 — intervention group
Group type: COMPARATOR
Intervention: Saline Control
Number of subjects: 32
Study 23673377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (RS)
Number of subjects: 465
Study 23673377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (RS) after adjustment
Number of subjects: 465
Study 21823911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 296
Study 21823911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 296
Study 21823911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day and 30 mg/day pooled
Number of subjects: 296
Study 21823911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 18521090 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 407
Study 16719877 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg x kg(‐1)) with diphenhydramine (1.25 mg x kg(‐1))
Number of subjects: 96
Study 16719877 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg x kg(‐1)) alone
Number of subjects: 96
Study 15553109 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 3 mg phenprocoumon
Number of subjects: 62
Study 15553109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool plasma analysis
Number of subjects: 62
Study 11219143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (FS)
Number of subjects: 100
Study 11219143 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Number of subjects: 100
Study 9489149 — intervention group
Group type: EXPERIMENTAL
Intervention: Reabsorbable microparticulate substance (Gelfoam)
Number of subjects: 13
Study 9489149 — intervention group
Group type: EXPERIMENTAL
Intervention: Non reabsorbable microparticulate substances (Ivalon, ITC contour, Terbal)
Number of subjects: 13
Study 8437318 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal nutrition (10 patients)
Number of subjects: 20
Study 8437318 — intervention group
Group type: COMPARATOR
Intervention: Systemic nutrition (10 patients)
Number of subjects: 20
Study 2875954 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 2875954 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 2875954 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol
Number of subjects: 0
Study 2875954 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 28972854 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of milk (MILK)
Number of subjects: 10
Study 28972854 — intervention group
Group type: COMPARATOR
Intervention: 500 mL of carbohydrate drink (CHO)
Number of subjects: 10
Study 26315481 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid combined with oral tacrolimus (TAC, target trough blood concentration of 4‐8 ng/mL)
Number of subjects: 90
Study 26315481 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CYC, 750 mg/m(2)/mo)
Number of subjects: 90
Study 26315481 — intervention group
Group type: COMPARATOR
Intervention: Oral mycophenolate mofetil (MMF, 1.5‐2.0 g/d)
Number of subjects: 90
Study 24887223 — intervention group
Group type: COMPARATOR
Intervention: S100A12 levels in TRALI patients
Number of subjects: 46
Study 24887223 — intervention group
Group type: COMPARATOR
Intervention: HMGB1 expression and levels of sRAGE in TRALI patients
Number of subjects: 46
Study 24887223 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention reported
Number of subjects: 46
Study 22354163 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 22354163 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 20644160 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0
Study 20644160 — intervention group
Group type: COMPARATOR
Intervention: Delayed BCG vaccination at 4 1/2 months
Number of subjects: 0
Study 18387999 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based laparoscopic simulator training
Number of subjects: 15
Study 18387999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study 16205453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 14
Study 16205453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12683845 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature modulation between 38 and 22 degrees C for multiple cycles
Number of subjects: 0
Study 12683845 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature modulation conditions
Number of subjects: 0
Study 10575809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 10575809 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study 9138754 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS cases
Number of subjects: 23
Study 9138754 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's cases
Number of subjects: 23
Study 9138754 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive asymptomatic cases
Number of subjects: 23
Study 9138754 — intervention group
Group type: COMPARATOR
Intervention: Seronegative asymptomatic cases
Number of subjects: 23
Study 9138754 — intervention group
Group type: COMPARATOR
Intervention: Non-infected control cultures
Number of subjects: 23
Study 1677320 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MK-467
Number of subjects: 0
Study 1677320 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg MK-467
Number of subjects: 0
Study 1677320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6869349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg orally before meals and at bedtime
Number of subjects: 24
Study 6869349 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic treatment (mechanical fragmentation and instillation of papain solution)
Number of subjects: 24
Study 6869349 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term metoclopramide treatment
Number of subjects: 24
Study 31873985 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (10‐40 mg)
Number of subjects: 64
Study 31873985 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (100‐200 mg)
Number of subjects: 64
Study 31873985 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 64
Study 31873985 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 64
Study 30608864 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 298
Study 30608864 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 298